This page collects WhisperX intelligence signals tagged #gene editing. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Academic scientists pioneering custom gene-editing treatments for rare childhood diseases are facing a critical roadblock. The team behind the landmark treatment for Baby KJ reports that FDA reviewers are imposing stringent manufacturing and quality control standards. These requirements, they argue, are so demanding th...
A major Chinese research collaboration has successfully developed an improved CRISPR/Cas9 gene editing system, demonstrating its clinical application in treating β-Thalassaemia. This breakthrough follows the FDA's approval of the first CRISPR-based therapy for sickle-cell anemia just over two years ago, marking a signi...
Eli Lilly has entered a collaboration with AI-focused biotech Profluent to develop next-generation gene editors capable of inserting entire genes into patients, signaling a major escalation in the pharmaceutical giant's ambitions in genetic medicine. The deal structure includes up to $2.25 billion in milestone payments...
Sangamo Therapeutics, a genomic medicine company focused on gene editing, has received a formal notice from Nasdaq indicating potential delisting due to failure to meet continued listing standards. The filing, submitted to the SEC on April 29, 2026, under Item 3.01 of Form 8-K, reveals that the company was notified it ...